- Home
- ARQT vs KNSA Comparison
ARQT vs KNSA Comparison
Compare ARQT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- KNSA
- Stock Information
- Founded
- ARQT 2016
- KNSA 2015
- Country
- ARQT United States
- KNSA United Kingdom
- Employees
- ARQT N/A
- KNSA N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- ARQT Health Care
- KNSA Health Care
- Exchange
- ARQT Nasdaq
- KNSA Nasdaq
- Market Cap
- ARQT 1.7B
- KNSA 2.1B
- IPO Year
- ARQT 2020
- KNSA 2018
- Fundamental
- Price
- ARQT $13.89
- KNSA $27.24
- Analyst Decision
- ARQT Strong Buy
- KNSA Strong Buy
- Analyst Count
- ARQT 6
- KNSA 5
- Target Price
- ARQT $18.80
- KNSA $38.80
- AVG Volume (30 Days)
- ARQT 1.9M
- KNSA 1.1M
- Earning Date
- ARQT 08-13-2025
- KNSA 07-22-2025
- Dividend Yield
- ARQT N/A
- KNSA N/A
- EPS Growth
- ARQT N/A
- KNSA N/A
- EPS
- ARQT N/A
- KNSA N/A
- Revenue
- ARQT $212,819,000.00
- KNSA $481,166,000.00
- Revenue This Year
- ARQT $61.15
- KNSA $37.21
- Revenue Next Year
- ARQT $37.98
- KNSA $5.32
- P/E Ratio
- ARQT N/A
- KNSA N/A
- Revenue Growth
- ARQT 100.03
- KNSA 59.45
- 52 Week Low
- ARQT $7.86
- KNSA $17.38
- 52 Week High
- ARQT $17.75
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- ARQT 51.91
- KNSA 45.18
- Support Level
- ARQT $13.47
- KNSA $27.08
- Resistance Level
- ARQT $14.69
- KNSA $28.86
- Average True Range (ATR)
- ARQT 0.63
- KNSA 1.07
- MACD
- ARQT 0.05
- KNSA -0.30
- Stochastic Oscillator
- ARQT 68.53
- KNSA 16.87
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.